Polyphenols: Cancer: Heart disease: Bioavailability: Health claims
Human life expectancy continues to increase, so that in many countries middle age can be thought of as extending into the sixth or seventh decade of life (see Lutz et al. 1997) . Paradoxically, as a result of living longer, there has been a relative increase in diseases that tend to appear later in life. Circulatory diseases and cancers now account for > 66 % of the causes of mortality in countries with a high per capita gross national product, and the probability of suffering from these conditions increases exponentially with age. For example, cancer accounts for > 60 % of deaths in males aged between 55 and 64 years, but only 10 % in men < 35 years (World Health Organization, 1998) . Considerable epidemiological evidence suggests that habitual consumption of diets rich in fruit and vegetables decreases the risk of developing such conditions (Williams, 1995) , and that the mantra of 'five servings of fruit and vegetables each day' may well be good advice. As yet, it is not clear which components of plant-based foods are protective and what is their mechanism of action. Potentially protective effects have been ascribed to numerous phytochemicals, including folate, vitamins C and E, various carotenoids, Se, phyto-oestrogens and isothiocyanates. Despite this current scientific uncertainty, a huge range of products containing a myriad of phytochemicals are commercially available and marketed to convince the consumer that the holy grail of maintaining health can be achieved by the simple expedient of consuming such 'magic bullets'. Recently, much attention has focused on the possibility that polyphenolic products of the phenylpropanoid biosynthetic pathway in plants could also have a putative role in the prevention of chronic diseases. In addition to the widespread availability of polyphenol-rich extracts and supplements from commercial outlets, the presence of polyphenols in brands of generic products such as tea, wines, chocolates and soft drinks is also used to imply potential health benefits. While there is substantial evidence in vitro that polyphenols can influence numerous cellular processes that are potentially anti-carcinogenic and atherogenic, little is known about their bioavailability and metabolic fate. Consequently, it is unclear whether such analogous effects occur in vivo following consumption of polyphenol-rich foods. The aim of the present brief article is to consider whether the 'message' concerning the potential health benefits of polyphenols is being communicated appropriately, or whether enthusiastic marketing currently exceeds the current scientific evidence.
What are plant polyphenols?
Plants produce thousands of phenolic and polyphenolic compounds as secondary metabolites. They are essential to (Table 2) .
In vitro evidence for beneficial effects
Prospective studies relating estimated intakes or plasma concentrations of flavonoids to cancer and heart disease have given contradictory results (Knekt et al. 2002) . In contrast, numerous in vitro studies indicate that plant polyphenols can potentially affect diverse processes in mammalian cells that, if also occurring in vivo, could have anti-carcinogenic and anti-atherogenic implications. These processes include gene expression, apoptosis, platelet aggregation, blood vessel dilation, intercellular signalling, P-glycoprotein activation and the modulation of enzyme activities associated with carcinogen activation and detoxification (for review, see Duthie et al. 2000) . However, most marketing strategies tend to focus on the ability of many polyphenols to act as antioxidants. This approach is possibly unsurprising, as there is a substantial body of epidemiological and experimental literature suggesting that inadequate intakes of recognised nutritional antioxidants such as vitamin E, vitamin C and carotenoids can lead to oxidative damage of proteins, lipids and DNA in vivo. This outcome, in turn, may predispose the development of many chronic diseases (Diplock et al. 1998) .
Antioxidant effects
The antioxidant effectiveness of many polyphenols in vitro is essentially a result of the ease with which a H atom from an aromatic hydroxyl group is donated to a free radical and the ability of the aromatic structure to support an unpaired electron due to delocalisation around the π-electron system.
For example, using stopped-flow electron-spin-resonance spectrometry methodology to assess the stoichiometry of the process of H-atom transfer between polyphenols and synthetic radicals (Gardner et al. 1997) , it is clear that many polyphenols can undergo multiple H-atom or electron transfer steps. Moreover, antioxidant abilities of several polyphenols commonly found in the diet are comparable with those of vitamin E and vitamin C in organic (Table 3) and aqueous ( 1·84  3·27  1·14  2·82  3·18  1·74  3·24  1·01  2·96  3·68  0·20  0·04  4·08  1·06  3·66  1·83  3·75  3·83  3·49  8·47  9·64  2·14 *Values are expressed as the no. of radicals reduced per mg. The antioxidant capacities were determined from the ability of the compounds to reduce the galvinoxyl radical using electron spin resonance spectroscopy. For details of method, see Gardner et al. (1997) . 1·18  0·89  2·24  1·88  2·56  2·96  2·73  3·64  4·35  2·48 *Values are expressed as the no. of radicals reduced per mg. The antioxidant capacities were determined from the ability of solutions of the compounds to reduce Fremy's salt using electron spin resonance spectroscopy. For details of method, see Gardner et al. (1997) .
compounds need to be readily absorbed and transported to the relevant site within the cell for optimum function. In addition, they should not promote adverse reactions in the cell. However, as yet, little is known about the bioavailability and metabolic fate of polyphenols. Consequently, the disparity between the epidemiological studies and in vitro data may reflect, in part, relatively poor bioavailability and rapid metabolism and excretion of such compounds when ingested. For example, within 60 min of rats consuming [2-14 C]quercetin-4′-glucoside in a dose equivalent to a 70 kg human subject consuming 250 g onions, nineteen deglycosylated, glucuronidated, sulfated and methylated metabolites were detected in non-intestinal tissues, traces of the original compound being only found in the small intestine, where extensive glucuronidation had also occurred (Mullen et al. 2003) . Moreover, those polyphenols with more potent antioxidant activity in vitro may be the most extensively metabolised in vivo compared with those with less oxidisable arrangements of the hydroxyl groups on the ring structures (Rice-Evans, 2001 ).
Bioavailability and metabolism
The absorption characteristics and subsequent metabolic fate of a polyphenol will probably depend on its individual structure. In general, however, studies to date suggest that 75-99 % of the ingested polyphenols are not detected in urine, which implies they have not been absorbed through the gut barrier, absorbed and excreted in the bile or metabolised by the colonic microflora or by the tissues. In addition, saturation of metabolic pathways by 'pharmacological' doses appears to be required to obtain the free form in the blood (Scalbert & Williamson, 2000) . Ingestion of nutritionally-relevant amounts results in extensive deglycosylation, glucuronidation, sulfation and methylation reactions mediated by a range of enzymes in the small intestine, liver and colon. These reactions include cytosolic β-glucosidases (small intestine, liver), lactase phlorozin hydrolase (small intestine), UDP-glucuronosyltransferases (intestine, liver), sulfotransferases (e.g. colon) and catechol-O-methyltransferases (liver; see Scalbert & Williamson, 2000; Williamson et al. 2000; Rice-Evans, 2001) . Such extensive metabolism is characteristic of the body's way of dealing with a potentially-toxic insult, and may be a reflection of one of the roles of polyphenols in plants, which is to discourage attack by fungal parasites, herbivorous grazers and pathogens. This explanation is also supported by the many studies that indicate mutagenic, genotoxic and clastogenic responses of cell cultures to certain polyphenols such as quercetin (Brusick, 1993) . On the other hand, there is very little evidence to date to suggest that dietary polyphenols promote adverse metabolic reactions in vivo when consumed in nutritionally-relevant quantities. However, as yet there is little clear evidence that polyphenols are putative dietary factors with important health benefits.
Conclusion
A deficiency in polyphenols does not cause any known clinical condition, unlike, for example, severe vitamin C deficiency causing scurvy and combined vitamin E and Se deficiencies resulting in myopathies and neuropathies (Combs, 1992) . Indeed, consumption of flavonoid-free diets by human volunteers has recently been reported to lead to a decrease in markers of oxidative stress commonly associated with enhanced disease risk (Young et al. 2002) . These authors speculate that this effect may be a response to a decrease in the intake of phytochemicals with potentially pro-oxidant effects. Until more is known about the mechanisms by which polyphenols are absorbed and metabolised, and the effects of the resulting conjugates and metabolites on cellular processes, it seems intuitively unwise to increase intakes by supplementation or food fortification or to promote them as a 'magic bullet'. This view is particularly apposite considering the unexpected adverse effects that were apparent in recent intervention trials with supplements of some of the well-recognised antioxidant nutrients (Omenn et al. 1996; Rapola et al. 1997 ).
